Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

CompletedOBSERVATIONAL
Enrollment

170

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

May 28, 2024

Study Completion Date

May 28, 2024

Conditions
Severe Eosinophilic Asthma
Interventions
OTHER

Survey Administration

Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.

Trial Locations (20)

T2N 1N4

Research Site, Calgary

T3B 0M3

Research Site, Calgary

T5H 4B9

Research Site, Edmonton

T5J 3S9

Research Site, Edmonton

T4N 1L1

Research Site, Red Deer

T8H 0N2

Research Site, Sherwood Park

V5Z 4E1

Research Site, Vancouver

V6Z 1Y6

Research Site, Vancouver

E2A 1A9

Research Site, Bathurst

L1S 2J5

Research Site, Ajax

L7N 3V2

Research Site, Burlington

N2M 5E2

Research Site, Kitchener

P1B 4Y3

Research Site, North Bay

M4V 1R2

Research Site, Toronto

M5G 1E2

Research Site, Toronto

L4N 7L3

Research Site, Barrie

J6E 2B4

Research Site, Saint-Charles-Borromée

G8T 7A1

Research Site, Trois-Rivières

S4P 1Y8

Research Site, Regina

S7N 0W8

Research Site, Saskatoon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY